Search - Prime Therapeutics - Portal

366 Results for GLP-1 Pipeline Update

Forbes: At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients

Forbes

PA Sub-Categories: GLP-1 Prime Article: In the News
U.S. News & World Report: Only 1 in 4 Still Taking Ozempic, Wegovy for Weight Loss Two Years Later

U.S. News & World Report

PA Sub-Categories: GLP-1 Prime Article: In the News
Drug Approvals Monthly Update: March 2024

Read Drug Approvals Monthly Update: March 2024 Critical updates in an ever-changing environment Drug Approval Update Specialty New drugs 3/13/2024 Tevimbra™ (tislelizumab-jsgr) Tevimbra, a...
Forbes: Study Shows 85% Of Patients Discontinue GLP-1s For Weight Loss After 2 Years

Forbes

PA Sub-Categories: GLP-1 Prime Article: In the News

Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
Page 19
Page 20
Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Page 41
Page 92

Login Portals

Compliance / Legal

Careers

© 2025 Prime Therapeutics LLC